Navigation Links
Malignant virus in polio vaccine combined to Cancer

ch has also turned up SV40 in tumors of children and adults born after the contaminated vaccine was taken off the market in 1963, leading to the still-unsolved mystery of how the virus is being transmitted. Friday's reports indicate that SV40 may be involved in a much broader group of human cancers, playing a possible role in nearly half of the 50,000 new cases of non- Hodgkin lymphoma diagnosed annually.

The cancer, which can be highly aggressive, has been associated with HIV-positive patients, and it was thought that the suppression of the immune system in these patients may have had a connection with the dramatic increase in lymphomas since 1970.

The new studies examined lymphomas from HIV-positive and -negative patients. Results suggested that both groups had either about the same level of SV40 DNA fragments, or that the HIV- negative samples had a greater incidence.

The second group of researchers were at the Fred Hutchinson Cancer Research Center in Seattle and the University of Texas Southwestern Medical Center in Dallas. Remarkably, both groups of researchers using slightly different detection techniques came up with almost identical results: SV40 fragments were found in 42 percent of 154 lymphomas sampled in one study, while the other found 43 percent in 68 cases.

No virus was detected by either study in nonmalignant lymphoid samples and other cancers used as controls. A Chronicle investigation reported last year that there is a heated controversy surrounding detection of SV40 and that most U.S. government's studies over the past decade have debunked the theory that SV40 is causing human cancer or even present in tumors.

But The Chronicle found that more than 60 studies from 30 laboratories around the world have reported detections of the virus in human malignancies. Dr. Jay A. Levy, a renowned virologist ``I've been in meetings where people say there is nothing to it,'' said at the University of Californ
'"/>




Page: 1 2 3

Related medicine news :

1. Malignant Mesothelioma – A New Genetic Revelatio
2. Malignant Mesothelioma – A New Genetic Revelation
3. Experimental Therapy Effective Against Malignant Melanoma in Horses
4. Protein Involved In Embryo Formation Found In Malignant Cells
5. Novel Suicide Gene Therapy Used to Treat Malignant Brain Tumors
6. Detection of Malignant Breast Tumors Made Simpler and More Effective
7. Minor mutations in HIV virus
8. Infertility in relation with virus
9. Birds breed viruses
10. Hidden influenza virus protein found
11. Hepatitis E virus made impotent
Post Your Comments:
Other Medicine News:Health News:Prime Healthcare Services to Acquire Three Hospitals from Tenet Healthcare Corporation 2Health News:Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs 2Health News:Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs 3Health News:Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs 4Health News:More girls than boys benefit from breastfeeding, Hopkins Children's research shows 2Health News:More girls than boys benefit from breastfeeding, Hopkins Children's research shows 3Health News:Bunk beds pose dangers to kids and adults 2Health News:Bunk beds pose dangers to kids and adults 3Health News:Large study identifies most costly adverse events in children's hospitals 2Health News:First study to examine vitamin D insufficiency in pediatric patients with low bone density 2
Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 1Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 3Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 4Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 5Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 6Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 7Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 8Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 9Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 10Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 11ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 1ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 2ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 3Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 1Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 2